Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oryzon Genomics
Biotech
Oryzon med fails to improve borderline personality disorder
Oryzon will seek the FDA’s advice after a borderline personality disorder failed to impact symptoms or severity of the mental health condition.
Annalee Armstrong
Jan 7, 2024 4:17pm
John Mascola moves on from NIAID's R&D hub—Chutes and Ladders
Apr 1, 2022 9:30am
Roche dumps Oryzon’s epigenetic AML, solid tumor drug
Jul 20, 2017 8:10am
EuroBiotech: More Articles of Note
May 5, 2016 10:21am
